NO315307B1 - Sukkerbeleggblanding og komprimert tablett - Google Patents
Sukkerbeleggblanding og komprimert tablett Download PDFInfo
- Publication number
- NO315307B1 NO315307B1 NO19960191A NO960191A NO315307B1 NO 315307 B1 NO315307 B1 NO 315307B1 NO 19960191 A NO19960191 A NO 19960191A NO 960191 A NO960191 A NO 960191A NO 315307 B1 NO315307 B1 NO 315307B1
- Authority
- NO
- Norway
- Prior art keywords
- sugar coating
- sugar
- tablet
- microcrystalline cellulose
- steroid hormone
- Prior art date
Links
- 238000009495 sugar coating Methods 0.000 title claims abstract description 50
- 239000007891 compressed tablet Substances 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 title claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 26
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 26
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 26
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 25
- 239000003270 steroid hormone Substances 0.000 claims abstract description 20
- 150000003431 steroids Chemical class 0.000 claims abstract description 9
- 239000008199 coating composition Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims description 29
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical group C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 8
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229940035811 conjugated estrogen Drugs 0.000 claims description 5
- 229960000606 medrogestone Drugs 0.000 claims description 5
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 claims description 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- 229960004400 levonorgestrel Drugs 0.000 claims description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 2
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims description 2
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 claims description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 2
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 claims description 2
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims description 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 2
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 claims description 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 2
- 229960004976 desogestrel Drugs 0.000 claims description 2
- 229960003839 dienestrol Drugs 0.000 claims description 2
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 claims description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 2
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 229960001348 estriol Drugs 0.000 claims description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 229960003399 estrone Drugs 0.000 claims description 2
- 229960002568 ethinylestradiol Drugs 0.000 claims description 2
- 229960001460 ethylestrenol Drugs 0.000 claims description 2
- AOXRBFRFYPMWLR-XGXHKTLJSA-N ethylestrenol Chemical compound C1CC2=CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 AOXRBFRFYPMWLR-XGXHKTLJSA-N 0.000 claims description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 2
- 229960005352 gestodene Drugs 0.000 claims description 2
- 229950001996 hexestrol Drugs 0.000 claims description 2
- 229960002899 hydroxyprogesterone Drugs 0.000 claims description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
- 229960004296 megestrol acetate Drugs 0.000 claims description 2
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 2
- 229960001390 mestranol Drugs 0.000 claims description 2
- 229960003377 metandienone Drugs 0.000 claims description 2
- 229960001566 methyltestosterone Drugs 0.000 claims description 2
- 229940053934 norethindrone Drugs 0.000 claims description 2
- 229960001652 norethindrone acetate Drugs 0.000 claims description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
- 229960000417 norgestimate Drugs 0.000 claims description 2
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 2
- 229960000464 oxandrolone Drugs 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 claims description 2
- 229950008546 trimegestone Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 239000008298 dragée Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 239000007940 sugar coated tablet Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000009500 colour coating Methods 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sukkerbeleggblanding for påføring på en komprimert medisinsk tablett omfattende et sukker, en dose av steroidhormon og en steroidfrigjøringshastighetskontrollerende mengde av mikrokrystallinsk cellulose.
Description
Foreliggende oppfinnelse vedrører en sukkerbeleggblanding og en komprimert tablett.
I de siste tre tiår har det vært gjort betydelige an-strengelser for å identifisere fremgangsmåter for kontroll av frigjøringshastigheten av medikamenter fra farmasøytiske
tabletter. Eksipienter er blitt inkorporert i tablettkjerner for å kontrollere oppløsningen, og følgelig absorbsjonen, av medikamenter. Tabletter og sferoider er blitt belagt med polymerer for å tilveiebringe langsom, diffusjonskontrollert frigjøring eller setespesifikk frigjøring av medikamenter. Det er også blitt fremstilt tabletter og innkapslede sferoide doseringsformer inneholdende flere medikamenter, enten i blanding eller som atskilte tablettsjikt eller sferoider. Medikamentene tilveiebringes for å gjennomføre flere funksjoner eller for å gi synergisme. Slike tabletter er særlig anvendelige i de tilfeller hvor konvensjonell terapi tilsier anvendelse av mer enn ett medikament som har .for-skjellige, men forlikelige aktiviteter. For eksempel admini-streres ofte diuretiske midler sammen med antihypertensive midler, og progestasjonelle midler sammen med østrogener.
Sukkerbeleggblandingen ifølge oppfinnelsen omfatter et sukker, en fyllingsdose av et steroidhormon og en steriod-frigjøringshastighetskontrollerende mengde av mikrokrystallinsk cellulose.
Foretrukne utførelsesformer derav fremgår av kravene 2-4.
Ifølge denne oppfinnelse tilveiebringes videre en komprimert tablett inneholdende en tablettkjerne inneholdende konjugerte østrogener og et sukkerbelegg, hvori nevnte sukkerbelegg inkorporerer et steroidhormon og en frigjørings-hastighetskontrollerende mengde av mikrokrystallinsk cellulose.
De medisinske agenser som er tilstede i tablettkjernen kan omfatte et hvilket som helst slikt middel som
administreres konvensjonelt sammen med et steroid hormon.
Den sukkerbelagte tablett kan også avsluttes med fargebelegg
og poleres, slik det er vanlig med belagte tabletter.
Innholdet av tablettkjernen er ganske uavhengig av sukkerbelegget i den forstand at sukkerbelegget og steroidhormonet som dette inneholder, blir oppløst før sprengning av den komprimerte tablett og oppløsning av medikament-komponentene finner sted. Følgelig kan komponentene som anvendes i formuleringen av kjernetabletten omfatte farma-søytisk akseptable, vannløselige og/eller uløselige substanser såsom laktose, kalsiumfosfat, stivelse, kalsium-karbonat, dekstrose, sorbitol, mannitol, mikrokrystallinsk cellulose, sukrose, polyvinylpyrrolidon, metylcellulose, karboksymetyl-cellulose, alginater, hydroksypropylcellulose, hydroksypropyl-metylcellulose, etylcellulose, kroskaramellosenatrium, natriumstivelseglykolat, magnesium-stearat, stearinsyre, polyetylenglykol, natriumlaurylsulfat, kondensert silika, talkum, og lignende.
Sukkerbelegget som.inneholder steroidhormonet vil også inneholde en steroidfrigjøringshastighetskontrollerende mengde av mikrokrystallinsk cellulose og, under visse omstendigheter, polyvinylpyrrolidon, for å hjelpe til ved påføringen av sukkerbelegget.
Tablettkjernen fremstilles ved komprimering av en blanding, som fortrinnsvis er blitt granulert, av steroid-forlikelig medikament og andre farmasøytisk akseptable eksipienter. Tablettkjernen kan ha et ikke-plastifisert eller plastifisert forseglingsbelegg utformet til å modifisere medikamentfrigjøringsegenskapene til medikamentene som kjernen inneholder, eller til å beskytte den mot fuktighet og/eller oksygen.
Denne oppfinnelse tilveiebringer en forbedret,
komprimert tablett hvori, i tillegg til en konvensjonell indre tablett-kjerne inneholdende ett eller flere medikamenter som er farmakologisk forlikelige med steroidet i det ytre sukkkerbelegg det er tilstede i, et sukkerbelegg
som omfatter et steroid hormon i en mengde på 0,1 til 20 vekt% av sukkerbelegget; mikrokrystallinsk cellulose i en mengde fra 0,1 til 3 vekt% av sukkerbelegget;
polyvinylpyrrolidon fra 0 til 5 vekt% av sukkerbelegget; og sukker. På enhetsdosebasis vil tabletten inneholde 0,05 til 50 mg, fortrinnsvis 0,1 til 30 mg, av steroidhormon i det fyllte sukkerbeleggsjikt. Om ønsket kan det påføres et underbelegg av inert, fyllt sukker over et forseglingsbelegg før det steroidfyllte sukkerbeleggsjikt. Det inerte fyll-stoff holdige undersjiktsukkerbelegg kan lages med sukrose inneholdende 7,5 til 15 % mikrokrystallinsk cellulose.
Det ytre sukkerbelegg kan inneholde et fargemiddel såsom
■ titandioksyd eller en primær, sekundær eller gråfarget sjat-tering som det er vanlig i tabletteringsteknologien. Om ønsket, kan fargemiddelet påføres som et atskilt beleggsjikt over det ytre sukkersjikt. En avsluttende polering kan full-føre tabletten..
Sukkeret som anvendes ved fremstillingen av sukkerbeleggene som det refereres til gjennom hele denne beskrivelse, er et sukkerprodukt såsom sukrose, avledet fra sukkerroe eller sukkerrør eller stivelse, sakkarid- eller polysakkarid-omdannede kilder, som blir ansett som egnet for t tablettbeleggings-formål. Det her foretrukne sukker er sukrose.
Det er blitt oppdaget at frigjøringen av et steroid hormon fra sukkerbelegget kan kontrolleres ved å begrense mengden av mikrokrystallinsk cellulose til fra ca. 0,1 til ca. 3 vekt% av sukkerbelegget. Denne anvendelse av en liten mengde mikrokrystallinsk cellulose i sukkerbelegget, er ulik anvendelsen av denne eksipient som et komprimeringshjelpe-middel eller til å assistere ved disintegrering av en tablett-kjerne. I sistnevnte tilfelle kan konsentrasjonen av mikro-krystallinsk cellulose stige til så meget som 15 til 30 vekt%.
Eksempler på steroidhormoner som egner seg for inkorporering i sukkerbeleggformuleringene ifølge denne oppfinnelse, omfatter medroksyprogesteron-acetat, levonorgestrel, gestoden, medrogeston, østradiol, østriol, etinyløstradiol, mestranol, østron, dienøstrol, heksøstrol,
dietylstilbøstrol, progesteron, desogestrel, norgestimat, hydroksyprogesteron, noretindron, noretindronacetat,. norgestrel, megestrolacetat, metyltestosteron, etyløstrenol, metandienon, oksandrolon, trimegeston og lignende.
For å illustrere in vitro oppløsningshastighetskontroll av steroid i fravær og nærvær av mikrokrystallinsk cellulose, presenteres følgende illustrerende eksempler uten begrensning:
EKSEMPEL 1
Et sukkerbelegg bestående av følgende faste stoffer ble påført over en tablettkjerne ved anvendelse av enten en ikke-perforert eller en perforert beleggingspanne:
Oppløsningshastigheten av steroidet ble bestemt ifølge <711> av USP XX, p. 959 (1980), ved anvendelse av Apparat 2, operert ved 50 opm ved oppløsning i 0,54% natriumlaurylsulfat i vann ved 37°C i seks gjentatte forsøk (Metode A). CV representerer variasjonskoeffisienten mellom disse forsøk uttrykt som en prosentsats.
EKSEMPEL 2
Tabletter belagt på samme måte med det samme sukkerbelegg som ovenfor ble løst i 0,13% natriumlaurylsulfat i
0,1 N HC1 ved 37°C ved anvendelse av USP Apparat 1 ved 100 opm, i seks forsøk (metode B). Resultatene av denne studie var:
EKSEMPEL 3
Ytterligere tabletter belagt på samme måte med den samme sukkerblanding ble underkastet en gjennomstrømnings-oppløs-ningstestfremgangsmåte i 0,12 % natriumlaurylsulfat i 0,1 N
HC1 ved 37°C ved anvendelse av et SOTAX Dissotest. Apparat ved 5,7 ml/min. strømningshastighet (Metode C). Resultatene av 3 atskilte forsøk var som følger:
Fra disse in vitro studier er det klart at medroksy-progesteronacetat, anvendt her som et typisk steroidhormon, blir frigjort fra sukkerbelegget ekstremt hurtig.
EKSEMPEL 4
For sammenligningsformål, og for å illustrere de uventede egenskaper av sukkerbeleggene ifølge denne oppfinnelse, ble et sukkerbelegg bestående av de følgende faste stoffer påført over en tablettkjerne:
Ved anvendelse av de mikrokrystallinsk celluloseholdige, sukkerbelagte tabletter og ved å følge Metode A, ble følgende
in vitro oppløsningsdata oppnådd fra 3 forsøk:
EKSEMPEL 5
Med ytterligere mikrokrystallinsk celluloseholdige sukkerbelagte tabletter fremstilt på samme måte som ovenfor, og ved å følge Metode B i seks forsøk, ble følgende data oppnådd:
EKSEMPEL 6
Og, ved å følge Metode C, med tablettene inneholdende mikrokrystallinsk cellulose i sukkerbelegget, i 3 forsøk, ble følgende data oppnådd:
Ut fra disse data er det åpenbart at en liten mengde mikrokrystallinsk cellulose i sukkerbelegget (i dette tilfellet 0,5 vekt% av de faste stoffer i sukkerbelegget) markert har retardert frigjøringshastigheten for steroidhormon.
EKSEMPEL 7
Det ble fremstilt sukkerbelagte tabletter hvori sukkerbelegget inneholdt 0.0%, 0,5% eller 2% mikrokrystallinsk cellu-lose i kombinasjon med 3,0% polyvinylpyrrolidon, 10,0% medroksyprogesteronacetat og sukrose. Disse tabletter ble gitt til 4 beaglehunder under fastende betingelser, og blod-plasmanivået av steroid ble bestemt ved 0, 0,5, 1, 1,5, 2, 3, 5, 8, 12, 16 og 24 timer. De resulterende data ble avsatt og arealet under kurven (AUC) beregnet for en 24 timers periode, og den tid hvorved maksimum plasmakonsentrasjon opptrådde ble bestemt til å være som følger:
Fra disse in vivo hundedata, er det åpenbart at det opptrer en markert forandring i biotilgjengelighet av et steroid hormon ettersom konsentrasjonen av mikrokrystallinsk cellulose i sukkerbelegget øker fra 0,0 til et som inneholder 0,5 til 2,0% mikrokrystallinsk cellulose. Frigjøringshastig-heten for steroidhormon inkorporert i et sukkerbelegg kan således kontrolleres ved inkorporering av svært små mengder av mikrokrystallinsk cellulose i sukkerbelegget.
EKSEMPEL 8
Det ble fremstilt sukkerbelagte tabletter hvori sukkerbelegget inneholdt 0,25%, 0,5% eller 0,8% mikrokrystallinsk cellulose i kombinasjon med 0,5% polyvinylpyrrolidon, 5,0% medroksyprogesteronacetat og sukrose. Disse tabletter ble underkastet en in vitro oppløsningstest ved anvendelse av USP Disintegration Apparatus (USP XX, <201>, p 958) (1980) med et 0,54% natriumlaurylsulfat-oppløsningsmedium ved 37°C.
Følgende testdata ble oppnådd:
Disse doseringsformer ble også evaluert i en human bio-tilgjengelighetsstudie. Doseringsformene ble administrert i en kryss-over design til tolv friske, kvinnelige individer.
Blodprøver ble oppsamlet ved 0,5, 1, 1,5, 2, 2,5, 3, 4,5,
6, 8 og 12 timer, og plasma analysert for
medroksyprogesteronacetat. Følgende data ble oppnådd:
Ut fra data for in vitro oppløsningen og in vivo human biotilgjengelighet, er det klart at medikamentfrigjørings-egenskapene og biotilgjengeligheten av steroidhormonet, blir kontrollert av konsentrasjonen av mikrokrystallinsk cellulose i sukkerbelegget.
EKSEMPEL 9
Et sukkerbelegg inneholdende 5 mg medrogeston i en matriks av sukrose med 0,4% mikrokrystallinsk cellulose og 0,5% polyvinylpyrrolidon ble påført på en forseglet og sukker-belagt tablettkjerne. In vitro oppløsningsprofilen " av denne doseringsform ble sammenlignet med den for en hurtig disinte-grerende komprimert tablett inneholdende 5 mg medrogeston ved anvendelse av oppløsningstesten beskrevet i
<711> av USP XX, p 959 (1980) ved anvendelse av Apparat 2 som opererte ved 50 opm, med 900 ml av 0,54% natriumlaurylsulfat ved 37°C. Følgende data ble oppnådd:
Den dramatiske effekt av redusert oppløsning av medro-geston når hormonet er inkorporert i et sukkerbelegg inneholdende 0,4 mikrokrystallinsk cellulose, er klart demon-strert .
En foretrukket utførelse av denne oppfinnelse er en komprimert tablett hvori tablettkjernen inneholder en enhetsdose av en østrogenforbindelse eller en blanding derav i en mengde på fra 0,1 til 5,0 mg, eller mer fortrinnsvis fra 0,3 til 2,5 mg, i kombinasjon med standard eksipient komprimeringshjelpemidler og fyllstoffer. Mest ønskelig vil de konjugerte østrogener som finnes i tablettkjernen omfatte det naturlig forekommende konjugerte østrogenprodukt kjent som Premarin™. Over et sukkerbelegg på den komprimerte tablett blir det påført et ytterligere sukkerbelegg inneholdende 1 til 50 mg, og fortrinnsvis 1,5 til 30 mg, av medroksy-progesteronacetat, et fargebelegg, og til slutt et polerings-belegg.
Claims (7)
1. Sukkerbeleggblanding for påføring på en komprimert medisinsk tablett,
karakterisert ved at den omfatter et sukker, en fyllingsdose av et steroidhormon og en steroidfrigjøringshastighets-
kontrollerende mengde av mikrokrystallinsk cellulose.
2. Sukkerbeleggblanding ifølge krav 1, karakterisert ved at sukkeret et sukrose.
3. Sukkerbeleggblanding ifølge krav 1, karakterisert ved at nevnte steroidhormon er medroksyprogesteronacetat, levonorgestrel, gestoden, medro-geston, østradiol, østriol, etinyløstradiol, mestranol,
østron, dienøstrol, heksøstrol, dietylstilbestrol, pro
gesteron, desogestrel, norgestimat, hydroksyprogesteron, noretindron, noretindronacetat, norgestrel, megestrolacetat, metyltestosteron, etyløstrenol, metandienon, oksandrolon eller trimegeston.
4. Sukkerbeleggblanding ifølge krav 1, karakterisert ved sukrose, fra 0,1 til 3 vekt% mikrokrystallinsk cellulose, polyvinylpyrrolidon i en mengde på fra 0 til 5% vekt%, et steroidhormon i en mengde på fra 0,1 til 20 vekt% og oppløsningsvann.
5. Komprimert tablett,
karakterisert ved en tablettkjerne inneholdende konjugerte østrogener og et sukkerbelegg, hvori nevnte sukkerbelegg inkorporerer et steroidhormon og en fri-gjøringshastighetskontrollerende mengde av mikrokrystallinsk cellulose.
6. Komprimert tablett ifølge krav 5, karakterisert ved at nevnte tablettkjerne inneholder fra 0,1 til 5,0 mg konjugerte østrogener, og nevnte sukkerbelegg inneholder fra 1,0 til 50 mg av nevnte steroidhormon.
7. Komprimert tablett ifølge krav 5, karakterisert ved at nevnte tablettkjerne inneholder fra 0,3 til 2,5 mg konjugerte østrogener og at nevnte sukkerbelegg inneholder 1,5 til 30 mg medroksy-progesteronacetat .
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/373,667 US5547948A (en) | 1995-01-17 | 1995-01-17 | Controlled release of steroids from sugar coatings |
Publications (3)
Publication Number | Publication Date |
---|---|
NO960191D0 NO960191D0 (no) | 1996-01-16 |
NO960191L NO960191L (no) | 1996-07-18 |
NO315307B1 true NO315307B1 (no) | 2003-08-18 |
Family
ID=23473354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19960191A NO315307B1 (no) | 1995-01-17 | 1996-01-16 | Sukkerbeleggblanding og komprimert tablett |
Country Status (35)
Country | Link |
---|---|
US (2) | US5547948A (no) |
EP (1) | EP0722720B1 (no) |
JP (1) | JP3833292B2 (no) |
KR (1) | KR100338581B1 (no) |
CN (1) | CN1106839C (no) |
AR (1) | AR002019A1 (no) |
AT (1) | ATE185482T1 (no) |
AU (1) | AU705879B2 (no) |
BR (1) | BR9600100B1 (no) |
CA (1) | CA2167254A1 (no) |
CO (1) | CO4370096A1 (no) |
CZ (1) | CZ286102B6 (no) |
DE (1) | DE69604600T2 (no) |
DK (1) | DK0722720T3 (no) |
EE (1) | EE03802B1 (no) |
EG (1) | EG23687A (no) |
ES (1) | ES2137627T3 (no) |
FI (1) | FI117592B (no) |
GR (1) | GR3031920T3 (no) |
HK (1) | HK1009935A1 (no) |
HU (1) | HU223781B1 (no) |
ID (1) | ID23996A (no) |
IL (1) | IL116772A (no) |
IS (1) | IS1878B (no) |
MY (1) | MY115786A (no) |
NO (1) | NO315307B1 (no) |
NZ (1) | NZ280826A (no) |
PL (1) | PL183330B1 (no) |
RU (1) | RU2152207C1 (no) |
SI (1) | SI0722720T1 (no) |
SK (1) | SK280484B6 (no) |
TR (1) | TR199600038A2 (no) |
TW (1) | TW460301B (no) |
UA (1) | UA37236C2 (no) |
ZA (1) | ZA96301B (no) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US6479475B1 (en) * | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
US6451778B1 (en) * | 1996-07-26 | 2002-09-17 | Wyeth | Oral contraceptive |
CA2230748C (en) * | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
DE19715594A1 (de) | 1997-04-15 | 1998-10-22 | Bayer Ag | Analgetika-Kombination |
HUP0003341A3 (en) * | 1997-06-13 | 2001-03-28 | Wyeth Corp | Rapamycin formulations for oral administration |
US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
US6432448B1 (en) | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
US6723342B1 (en) | 1999-02-08 | 2004-04-20 | Fmc Corporation | Edible coating composition |
US6500462B1 (en) | 1999-10-29 | 2002-12-31 | Fmc Corporation | Edible MCC/PGA coating composition |
AT500063A1 (de) | 1999-11-23 | 2005-10-15 | Sandoz Ag | Beschichtete tablettenkerne |
FR2801218B1 (fr) * | 1999-11-23 | 2001-12-28 | Hoechst Marion Roussel Inc | Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant |
US6855703B1 (en) | 2000-03-10 | 2005-02-15 | Endeavor Pharmaceuticals | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
US7459445B2 (en) * | 2000-03-10 | 2008-12-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and topical pharmaceutical formulations of the same |
US6660726B2 (en) * | 2000-03-10 | 2003-12-09 | Endeavor Pharmaceuticals | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
US7989436B2 (en) | 2003-07-23 | 2011-08-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and pharmaceutical formulations comprising the same |
US20010034340A1 (en) * | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
IL155959A0 (en) | 2000-11-28 | 2003-12-23 | Fmc Corp | Edible pga (propylene glycol alginate) coating composition |
US7303763B2 (en) * | 2001-02-12 | 2007-12-04 | Watson Laboratories, Inc. | Compositions for conjugated estrogens and associated methods |
US6630166B1 (en) * | 2001-02-12 | 2003-10-07 | Watson Pharmaceuticals, Inc. | Compositions for conjugated estrogens and associated methods |
IL157943A0 (en) * | 2001-03-16 | 2004-03-28 | Wyeth Corp | Estrogen replacement therapy |
CN1555266A (zh) * | 2001-03-16 | 2004-12-15 | 激素替代疗法 | |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
TW200306196A (en) * | 2002-04-03 | 2003-11-16 | Wyeth Corp | Hormone replacement therapy |
TW200306846A (en) * | 2002-04-03 | 2003-12-01 | Wyeth Corp | Hormone replacement therapy |
TW200306851A (en) * | 2002-04-29 | 2003-12-01 | Wyeth Corp | Hormone replacement therapy |
TW200400040A (en) * | 2002-05-17 | 2004-01-01 | Wyeth Corp | Hormone replacement therapy |
US6992075B2 (en) * | 2003-04-04 | 2006-01-31 | Barr Laboratories, Inc. | C(14) estrogenic compounds |
CA2521471A1 (en) * | 2003-04-11 | 2004-10-28 | Barr Laboratories, Inc. | Methods of administering estrogens and progestins |
ES2933479T3 (es) * | 2003-09-29 | 2023-02-09 | Novo Nordisk Healthcare Ag | Estabilidad mejorada de formulaciones de progestágenos |
TW200602089A (en) * | 2004-06-07 | 2006-01-16 | Wyeth Corp | Sugar coatings and methods therefor |
MX2007003519A (es) * | 2004-09-23 | 2007-08-07 | Fmc Corp | Composicion de recubrimiento. |
EP1853272A1 (en) * | 2005-02-03 | 2007-11-14 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
CN101252921A (zh) * | 2005-06-29 | 2008-08-27 | 惠氏公司 | 轭合雌激素类物质和苯卓昔芬的制剂 |
JP2010509350A (ja) * | 2006-11-07 | 2010-03-25 | ワイス エルエルシー | 糖コーティングおよびその方法 |
CL2007003429A1 (es) * | 2006-11-29 | 2008-04-11 | Wyeth Corp | Tableta bi-capa que comprende una primera capa con al menos un estrogeno y una segunda capa con uno o mas agentes terapeuticos seleccionados entre un modulador selectivo del receptor de estrogeno y un agente progestacional; proceso de produccion, uti |
WO2012120365A1 (en) | 2011-03-07 | 2012-09-13 | Aurobindo Pharma Limited | Stable pharmaceutical composition comprising ethinyl estradiol |
MX353623B (es) * | 2011-05-13 | 2018-01-22 | Eb Ip Hybritabs B V | Sistema de suministro de farmaco. |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10808210B2 (en) | 2013-03-15 | 2020-10-20 | Monosol, Llc | Water-soluble film for delayed release |
WO2014151718A2 (en) * | 2013-03-15 | 2014-09-25 | Monosol Llc | Water-soluble film for delayed release |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB844772A (en) * | 1956-04-19 | 1960-08-17 | Pfizer & Co C | Granular pharmaceutical compositions and process for preparing same |
GB888631A (en) * | 1959-02-24 | 1962-01-31 | Upjohn Co | Improvements in or relating to oral therapeutic compositions comprising steroids |
FR1396710A (fr) * | 1964-06-15 | 1965-04-23 | Diwag Chemische Fabriken G M B | Procédé pour la fabrication de charges ou supports perfectionnés et produits obtenus |
US3980766A (en) * | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US4154820A (en) * | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
US4248856A (en) * | 1979-07-10 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4309404A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4327076A (en) * | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4425339A (en) * | 1981-04-09 | 1984-01-10 | Syntex (U.S.A.) Inc. | Treatment of menopausal symptoms |
US4415546A (en) * | 1981-05-12 | 1983-11-15 | Janakiraman Ramachandran | Biologically active analogs of ACTH and radioimmuno assay therefor |
US4390531A (en) * | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
US4415547A (en) * | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
JPS604120A (ja) * | 1983-06-22 | 1985-01-10 | Shionogi & Co Ltd | 作用持続型ピナシジル製剤 |
US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
GB8403360D0 (en) * | 1984-02-08 | 1984-03-14 | Erba Farmitalia | Pharmaceutical compositions |
EP0153105B1 (en) * | 1984-02-10 | 1992-09-09 | Benzon Pharma A/S | Diffusion coated multiple-units dosage form |
GB8414221D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Unit dosage form |
SE8404467D0 (sv) * | 1984-09-06 | 1984-09-06 | Ferrosan Ab | Controlled-release medical preparations |
US4755386A (en) * | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
GB8705083D0 (en) * | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US4927816A (en) * | 1987-08-20 | 1990-05-22 | Ester George C | Formulae and methods for sublingual ingestion of natural progesterone |
US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
JP2542122B2 (ja) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
US5223268A (en) * | 1991-05-16 | 1993-06-29 | Sterling Drug, Inc. | Low solubility drug-coated bead compositions |
JP3722294B2 (ja) * | 1993-02-23 | 2005-11-30 | ワーナー−ランバート・コンパニー | 実質的にアルコールを含有しない医薬組成物の製造方法 |
ZA949929B (en) * | 1993-12-23 | 1995-08-23 | Akzo Nobel Nv | Sugar-coated pharmaceutical dosage unit. |
US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
-
1995
- 1995-01-17 US US08/373,667 patent/US5547948A/en not_active Expired - Lifetime
-
1996
- 1996-01-10 AR ARP960100946A patent/AR002019A1/es unknown
- 1996-01-11 EE EE9600002A patent/EE03802B1/xx unknown
- 1996-01-11 SK SK49-96A patent/SK280484B6/sk not_active IP Right Cessation
- 1996-01-12 JP JP00368196A patent/JP3833292B2/ja not_active Expired - Lifetime
- 1996-01-15 AU AU40982/96A patent/AU705879B2/en not_active Expired
- 1996-01-15 ID IDP990833D patent/ID23996A/id unknown
- 1996-01-15 DK DK96300284T patent/DK0722720T3/da active
- 1996-01-15 ES ES96300284T patent/ES2137627T3/es not_active Expired - Lifetime
- 1996-01-15 AT AT96300284T patent/ATE185482T1/de active
- 1996-01-15 SI SI9630070T patent/SI0722720T1/xx unknown
- 1996-01-15 RU RU96100843/14A patent/RU2152207C1/ru active
- 1996-01-15 ZA ZA96301A patent/ZA96301B/xx unknown
- 1996-01-15 IS IS4318A patent/IS1878B/is unknown
- 1996-01-15 EP EP96300284A patent/EP0722720B1/en not_active Expired - Lifetime
- 1996-01-15 CA CA002167254A patent/CA2167254A1/en not_active Abandoned
- 1996-01-15 NZ NZ280826A patent/NZ280826A/en not_active IP Right Cessation
- 1996-01-15 MY MYPI96000145A patent/MY115786A/en unknown
- 1996-01-15 DE DE69604600T patent/DE69604600T2/de not_active Expired - Lifetime
- 1996-01-15 CO CO96001228A patent/CO4370096A1/es unknown
- 1996-01-16 BR BRPI9600100-3A patent/BR9600100B1/pt active IP Right Grant
- 1996-01-16 FI FI960210A patent/FI117592B/fi not_active IP Right Cessation
- 1996-01-16 UA UA96010195A patent/UA37236C2/uk unknown
- 1996-01-16 TR TR96/00038A patent/TR199600038A2/xx unknown
- 1996-01-16 PL PL96312336A patent/PL183330B1/pl unknown
- 1996-01-16 KR KR1019960000693A patent/KR100338581B1/ko not_active IP Right Cessation
- 1996-01-16 IL IL11677296A patent/IL116772A/xx not_active IP Right Cessation
- 1996-01-16 NO NO19960191A patent/NO315307B1/no not_active IP Right Cessation
- 1996-01-16 CZ CZ1996128A patent/CZ286102B6/cs not_active IP Right Cessation
- 1996-01-16 TW TW085100468A patent/TW460301B/zh not_active IP Right Cessation
- 1996-01-16 HU HU9600090A patent/HU223781B1/hu active IP Right Grant
- 1996-01-16 CN CN96104096A patent/CN1106839C/zh not_active Expired - Lifetime
- 1996-01-17 EG EG4796A patent/EG23687A/xx active
- 1996-04-10 US US08/631,876 patent/US5759576A/en not_active Expired - Lifetime
-
1998
- 1998-09-21 HK HK98110778A patent/HK1009935A1/xx not_active IP Right Cessation
-
1999
- 1999-11-23 GR GR990403011T patent/GR3031920T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO315307B1 (no) | Sukkerbeleggblanding og komprimert tablett | |
AU722188B2 (en) | Controlled release of steroids from sugar coatings | |
KR102539030B1 (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
EP1689372B1 (en) | Compositions for conjugated estrogens and associated methods | |
JP5484646B2 (ja) | 新規な避妊薬とその調製方法 | |
MXPA97000515A (en) | Controlled release of steroids from azu coatings |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |